The vaccine developed by researchers at Canadian biotechnology company Medicago contains coronavirus-like particles (CoVLP) produced in pla...

Vaccine developers only bringing shots to the testing phase now are finding it an uphill battle, with the developed world so highly vaccina...

The Paris-based company said it will continue to develop another vaccine candidate that is already undergoing late stage human trials. That...

The drug company is conducting phase-3 trials with over 20,000 participants to test whether its three-dose vaccine ZyCoV-D prevents virolog...

The shot was also 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is domina...

Six-to-eight new immunizations may complete clinical studies and undergo regulatory review by the end of the year, Soumya Swaminathan, the ...

Regulators around the world should be prepared for this by adapting to a pooled network of biomarkers to approve vaccines, the organisation...

Researchers say based on their trial, which involved about 20,000 people in Russia last fall, the vaccine is about 91 per cent effective an...

The vaccine maker said in briefing documents it submitted to the U.S. Food and Drug Administration released on Tuesday that it had not yet ...

The U.S. drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with a one-dose trial with as many as 60,0...

The jump to mass vaccinations presents new hurdles, in particular for an mRNA vaccine like Pfizer and BioNTech's that must be stored and sh...

Typically, regulators strive to have at least 95% certainty that the trial read-out is not the result of random variations with nothing to ...

The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that a...

The U.S. Food and Drug Administration has said it will not approve a vaccine unless it is both effective and safe. On Tuesday, it added mor...

Participants will be enrolled continuously during the trial and vaccine candidates that are not working will be dropped from testing.

In a statement, the company said “the placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine i...

Washington, Nov 29 (IANS) The first HIV vaccine efficacy study in seven years has begun in South Africa to test whether a modified vaccine ...